Sumatriptan-Vertex, 50 mg 2 pcs

Sumatriptan is an antimigraine agent. It is a specific and selective agonist of 5-NT1-serotonin receptors localized mainly in the blood vessels of the brain, and does not act on other subtypes of 5-NT-serotonin receptors (5-NT 2-7). < br>

Causes narrowing of the carotid arterial bed vessels, which supply blood to the extracranial and intracranial tissues (dilation of the cerebral membrane vessels and/or their edema is the main mechanism of migraine development in humans), while not having a significant effect on cerebral blood flow. < br>

Suppresses the activity of receptors of trigeminal nerve afferent fiber endings in the dura mater (as a result the release of sensory neuropeptides is reduced). It eliminates nausea and photophobia associated with migraine attack.

< br> In 50-70% of cases it quickly eliminates the attack when taken orally in a dose of 25-100 mg. Within 24 h, a relapse may occur in 1/3 of cases requiring reapplication. Onset of action is 30 min. After oral administration at a dose of 100 mg.

< br>.

Indications

Cutting migraine attacks with or without aura.

Active ingredient

Sumatriptan

Composition

1 film-coated tablet contains: sumatriptan succinate 140 (70) mg, in terms of sumatriptan 100 (50) mg.

Auxiliary substances:

Hyprolose (Clucel LF hydroxypropylcellulose),

calcium hydrophosphate dihydrate,

Mannitol (mannitol),

magnesium stearate,

croscarmellose sodium (primellose),

microcrystalline cellulose.

Composition of the film coating:

selekout AQ-02003 (hypromellose (hydroxypropyl methylcellulose),

macrogol (polyethylene glycol 6000),

titanium dioxide).

How to take, the dosage

– Hypersensitivity.

– Hemiplegic, basilar or ophthalmoplegic forms of migraine.

– Coronary heart disease (CHD) and its suspicion.

– Angina pectoris (including Prinzmetal’s angina).

– Myocardial infarction (including history).

– Arterial hypertension (uncontrolled).

– Peripheral arterial occlusive disease.

– Stroke or transient cerebral circulation disorder (including history).

– Hepatic or or renal insufficiency.

With caution should be used:
– Epilepsy (including any condition with reduced epileptic threshold).

– Arterial hypertension (controlled).

Pregnancy and lactation period.
– Childhood and adolescence under 18 years of age.
– Older age over 65 years.
– Simultaneous use of drugs containing ergotamine and its derivatives, as well as MAO inhibitors and the period up to 14 days after their withdrawal.

Interaction

In concomitant administration with ergotamine and ergotamine-containing drugs prolonged vasospasm is possible (interval between their administration should be at least 24h).

Possible interaction between sumatriptan and MAO inhibitors (decreased intensity of sumatriptan metabolism, increased concentration).

In concomitant use of sumatriptan and drugs from the group of selective serotonin reuptake inhibitors, weakness, hyperreflexia and impaired coordination of movements may occur.

Special Instructions

It is not intended for migraine prophylaxis (administration during migraine aura before other symptoms occur may not prevent the development of headache).

If there is no effect on the first dose, the diagnosis should be clarified. It should be borne in mind that in patients with migraine there is a risk of stroke or transient cerebral circulation disorders. When administered during lactation, it is not recommended to breastfeed the child for 24h after taking sumatriptan. Patients with hypersensitivity to sulfonamides when administering sumatriptan have an increased risk of allergic reactions (from skin manifestations to anaphylactic shock).

Patients with cardiovascular risk group should not start therapy without prior investigation (women in post-menopausal period, men over 40 years old, patients with CHD risk factors).

Before administering sumatriptan to patients with newly diagnosed or atypical migraine should exclude other potentially dangerous neurological diseases.

Experience with sumatriptan in patients over 65 years of age is limited (no significant difference in pharmacokinetics compared with younger patients).

Driving use:Cautious driving and engaging in other potential activities requiring increased concentration and rapid psychomotor reactions should be observed during treatment.

.

Contraindications

– Hypersensitivity.

– Hemiplegic, basilar or ophthalmoplegic forms of migraine.

– Coronary heart disease (CHD) and its suspicion.

– Angina pectoris (including Prinzmetal’s angina).

– Myocardial infarction (including history).

– Arterial hypertension (uncontrolled).

– Peripheral arterial occlusive disease.

– Stroke or transient cerebral circulation disorder (including history).

– Hepatic or or renal insufficiency.

With caution should be used:

– Epilepsy (including any condition with reduced epileptic threshold).

– Arterial hypertension (controlled).

Pregnancy and lactation period.
– Childhood and adolescence under 18 years of age.
– Older age over 65 years.
– Simultaneous use of drugs containing ergotamine and its derivatives, as well as MAO inhibitors And the period up to 14 days after their withdrawal.

.